Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease.
BACKGROUND
Gonadal damage in adult patients after chemotherapy for Hodgkin's disease is well documented, but data of patients treated before adulthood are scarce.


METHODS
Gonadal and hormonal function were studied in 19 male long term survivors of Hodgkin's disease who were treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP chemotherapy) before (n = 15) or during puberty (n = 4). The studies were performed a median of 10 years after treatment and repeated in the majority of the patients at the time of yearly visits.


RESULTS
Germ cell damage was present in all patients. Semen analysis revealed azoospermia in 12 patients and oligospermia in 6; no recovery of spermatogenesis was seen at follow-up. Testicular size was small in all but one patient. Follicle-stimulating hormone levels were elevated (mean, 14.4 +/- 7.8 U/l) and increased over time (mean, 21.1 +/- 10.5 U/l, P < 0.001). In seven patients, luteinizing hormone (LH) was elevated, indicating Leydig cell dysfunction; also in four of those patients, plasma testosterone was decreased. In three other patients, the response of LH to gonadotropin-releasing hormone was exaggerated with a normal basal LH and testosterone. Comparing testicular function of prepubescent versus pubescent state at time of treatment appears to show a trend for improved outcome in the younger patients.


CONCLUSIONS
Gonadal function of long term survivors of pediatric Hodgkin's disease treated with MOPP chemotherapy is severely impaired permanently.
Department of Internal Medicine, University of Amsterdam, The Netherlands.
J
J
Heikens
H
H
Behrendt
R
R
Adriaanse
A
A
Berghout
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002648:Child; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000097:blood; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects; D011241:Prednisone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D013076:Sperm Count / Q000187:drug effects*; D017741:Survivors; D014750:Vincristine / Q000009:adverse effects
D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D011241:Prednisone